These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 25204464

  • 1. Tasimelteon: a melatonin receptor agonist for non-24-hour sleep-wake disorder.
    Johnsa JD, Neville MW.
    Ann Pharmacother; 2014 Dec; 48(12):1636-41. PubMed ID: 25204464
    [Abstract] [Full Text] [Related]

  • 2. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.
    Lockley SW, Dressman MA, Licamele L, Xiao C, Fisher DM, Flynn-Evans EE, Hull JT, Torres R, Lavedan C, Polymeropoulos MH.
    Lancet; 2015 Oct 31; 386(10005):1754-64. PubMed ID: 26466871
    [Abstract] [Full Text] [Related]

  • 3. Tasimelteon for the treatment of non-24-hour sleep-wake disorder.
    Neubauer DN.
    Drugs Today (Barc); 2015 Jan 31; 51(1):29-35. PubMed ID: 25685859
    [Abstract] [Full Text] [Related]

  • 4. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders.
    Hardeland R.
    Curr Opin Investig Drugs; 2009 Jul 31; 10(7):691-701. PubMed ID: 19579175
    [Abstract] [Full Text] [Related]

  • 5. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.
    Rajaratnam SM, Polymeropoulos MH, Fisher DM, Roth T, Scott C, Birznieks G, Klerman EB.
    Lancet; 2009 Feb 07; 373(9662):482-91. PubMed ID: 19054552
    [Abstract] [Full Text] [Related]

  • 6. Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals.
    Keating GM.
    CNS Drugs; 2016 May 07; 30(5):461-8. PubMed ID: 27003694
    [Abstract] [Full Text] [Related]

  • 7. Tasimelteon for treating non-24-h sleep-wake rhythm disorder.
    Nishimon S, Nishimon M, Nishino S.
    Expert Opin Pharmacother; 2019 Jun 07; 20(9):1065-1073. PubMed ID: 30990759
    [Abstract] [Full Text] [Related]

  • 8. Tasimelteon (Hetlioz™): A New Melatonin Receptor Agonist for the Treatment of Non-24-Hour Sleep-Wake Disorder.
    Bonacci JM, Venci JV, Gandhi MA.
    J Pharm Pract; 2015 Oct 07; 28(5):473-8. PubMed ID: 25092604
    [Abstract] [Full Text] [Related]

  • 9. Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients.
    Stahl SM.
    CNS Spectr; 2014 Dec 07; 19(6):475-8. PubMed ID: 25422900
    [Abstract] [Full Text] [Related]

  • 10. Diagnosis and Treatment of Non-24-h Sleep-Wake Disorder in the Blind.
    Emens JS, Eastman CI.
    Drugs; 2017 Apr 07; 77(6):637-650. PubMed ID: 28229310
    [Abstract] [Full Text] [Related]

  • 11. Tasimelteon (Hetlioz) for non-24-hour sleep-wake disorder.
    Med Lett Drugs Ther; 2014 Apr 28; 56(1441):34-5. PubMed ID: 24759294
    [No Abstract] [Full Text] [Related]

  • 12. Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies.
    Leger D, Quera-Salva MA, Vecchierini MF, Ogrizek P, Perry CA, Dressman MA.
    Expert Opin Drug Saf; 2015 Apr 28; 14(11):1673-85. PubMed ID: 26393492
    [Abstract] [Full Text] [Related]

  • 13. Tasimelteon for insomnia.
    Lankford DA.
    Expert Opin Investig Drugs; 2011 Jul 28; 20(7):987-93. PubMed ID: 21548834
    [Abstract] [Full Text] [Related]

  • 14. Tasimelteon approved for circadian disorder in blind adults.
    Traynor K.
    Am J Health Syst Pharm; 2014 Mar 01; 71(5):350. PubMed ID: 24534583
    [No Abstract] [Full Text] [Related]

  • 15. Tasimelteon: a selective and unique receptor binding profile.
    Lavedan C, Forsberg M, Gentile AJ.
    Neuropharmacology; 2015 Apr 01; 91():142-7. PubMed ID: 25534555
    [Abstract] [Full Text] [Related]

  • 16. Comparative Review of Approved Melatonin Agonists for the Treatment of Circadian Rhythm Sleep-Wake Disorders.
    Williams WP, McLin DE, Dressman MA, Neubauer DN.
    Pharmacotherapy; 2016 Sep 01; 36(9):1028-41. PubMed ID: 27500861
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of the dual melatonin receptor agonist tasimelteon in subjects with hepatic or renal impairment.
    Torres R, Kramer WG, Baroldi P.
    J Clin Pharmacol; 2015 May 01; 55(5):525-33. PubMed ID: 25450415
    [Abstract] [Full Text] [Related]

  • 18. Tasimelteon: first global approval.
    Dhillon S, Clarke M.
    Drugs; 2014 Mar 01; 74(4):505-11. PubMed ID: 24610704
    [Abstract] [Full Text] [Related]

  • 19. Simulated driving performance in healthy adults after night-time administration of 20 mg tasimelteon.
    Torres R, Fisher M, Birznieks G, Polymeropoulos C, Kay GG, Xiao C, Polymeropoulos MH.
    J Sleep Res; 2022 Feb 01; 31(1):e13430. PubMed ID: 34152055
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders.
    Laudon M, Frydman-Marom A.
    Int J Mol Sci; 2014 Sep 09; 15(9):15924-50. PubMed ID: 25207602
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.